Welcome to our dedicated page for Parabilis Medicines news (Ticker: PBLS), a resource for investors and traders seeking the latest updates and insights on Parabilis Medicines stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Parabilis Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Parabilis Medicines's position in the market.
Parabilis Medicines (Nasdaq: PBLS) announced that its Chairman, President and CEO, Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The session is scheduled for 2:35 PM ET on Wednesday, September 16, 2026, with a live audio webcast available via the Investors section of the Parabilis website.
Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company, has appointed Craig L. Tendler, M.D. to its Board of Directors, while he continues as a scientific advisor. Dr. Tendler previously led late-stage clinical development and global medical affairs for oncology at Johnson & Johnson.
According to Parabilis Medicines, Dr. Tendler brings more than 30 years of oncology drug development experience, including involvement in over 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations and 15 New Molecular Entities. His expertise is expected to support advancement of zolucatetide and the company’s Helicon therapeutics pipeline.
Parabilis Medicines (Nasdaq: PBLS) reported second quarter 2026 results highlighted by a strategic collaboration with Regeneron and a completed upsized IPO. The Regeneron deal brought $125 million in upfront consideration and equity, with potential for up to approximately $2.2 billion in future milestone payments plus tiered royalties.
Parabilis raised $770.5 million in its IPO and ended June 30, 2026 with $1.1 billion in cash, cash equivalents and marketable securities, which is expected to fund operations into 2030. The company advanced lead Helicon™ candidate zolucatetide toward a planned Phase 3 trial in desmoid tumors and additional Wnt/β‑catenin-driven indications.
Quarterly R&D expenses were $39.4 million and G&A expenses were $11.7 million, leading to a net loss of $52.5 million, higher than the prior-year period primarily due to increased investment in clinical and preclinical programs and public-company infrastructure.
Parabilis Medicines (Nasdaq: PBLS) closed its upsized IPO of 38,525,000 common shares at $20.00 per share, including full exercise of the underwriters’ option. Shares started trading on June 10, 2026.
The company also closed a concurrent $75 million private placement to Regeneron and reported over $1.2 billion raised in 2026, with all preferred stock and a $50 million SAFE converting into common stock.
Parabilis Medicines (Nasdaq: PBLS) priced an upsized IPO of 33,500,000 shares at $20.00 per share, targeting $670 million in gross proceeds. Underwriters hold a 30-day option for 5,025,000 additional shares.
Trading on the Nasdaq Global Select Market is expected to start June 10, 2026. Parabilis also agreed to a concurrent private placement of 4,166,666 shares at $18.00 per share to Regeneron, for about $75 million in additional proceeds. Both offerings are expected to close around June 11, 2026, subject to customary conditions.